Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

C106

Small molecule · Agonist of angiotensin II type 2 receptor (AGTR2) · developed by Vicore Pharma

Phase 1 Most advanced trial (none active)
VCRE Developer
1 Registered trials

What is C106?

C106 is a selective nonpeptide agonist of the angiotensin II type 2 receptor (AT2R). It is being studied in idiopathic pulmonary fibrosis and pulmonary hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
angiotensin II type 2 receptor (AGTR2)
Mechanism
Agonist of angiotensin II type 2 receptor (AGTR2)
Therapy area
Cardiovascular, Respiratory
Developer
Vicore Pharma AB (VCRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05427253 Phase 1 Safety Issues Completed VCRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary FibrosisPulmonary HypertensionSafety IssuesTolerance

More from Vicore Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VCRE page.

Follow VCRE, the company behind C106

See VCRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VCRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.